Welcome to our dedicated page for Indivior news (Ticker: INVVY), a resource for investors and traders seeking the latest updates and insights on Indivior stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Indivior's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Indivior's position in the market.
Indivior PLC (LON: INDV) announced on June 8, 2021, a strategic collaboration with Aelis Farma to target cannabis-related disorders through AEF0117, a first-in-class synthetic Signaling Specific inhibitor. Indivior will invest $30 million for an exclusive global option for AEF0117, with the potential for additional payments totaling $100 million following successful Phase 2b trials. AEF0117 has demonstrated promising safety and efficacy in previous studies, addressing a significant public health need amid rising cannabis use.
Indivior PLC released findings from a study on the impact of COVID-19 on opioid use disorder (OUD) management in the U.S., revealing that 85% of participants noted increased barriers to care during the pandemic.
Key results include a 20% rise in relapse rates, 45% increase in overdose rates, and 25% decline in medication adherence. The study highlights the effectiveness of telemedicine but notes challenges for vulnerable populations. Overall, it underscores the need for improved access and support for OUD patients, whose treatment was significantly affected during the pandemic.
Indivior PLC (LON:INDV) urges public health dialogue to combat stigma surrounding opioid use disorder (OUD) amid COVID-19 challenges. Shatterproof, a nonprofit, launched a National Movement to End Addiction Stigma, addressing four stigma types affecting OUD patients. Statistics show that 14.9% of those needing treatment fear negative community perceptions. Less than 10% of OUD individuals received medication-assisted treatment in 2017. Indivior emphasizes the importance of collective efforts in addressing these issues to improve patient acceptance and treatment access.
Indivior PLC (LON: INDV) announced strategic organizational changes to enhance its focus on high-value opportunities and better align resources amid COVID-19 challenges. Key actions include reorganizing the U.S. commercial function, focusing R&D on post-marketing studies for SUBLOCADE® and PERSERIS®, and streamlining corporate functions to reduce discretionary spending. Indivior aims to cut operating expenses by $60m to $70m pre-tax in 2021, with a $6m restructuring charge expected in Q3 results. Business performance remains aligned with FY 2020 Planning Assumptions.